Agonist-induced ubiquitination of the b 2 adrenergic receptor (b 2 AR) functions as an important post-translational modification to sort internalized receptors to the lysosomes for degradation. We now show that this ubiquitination is reversed by two deubiquitinating enzymes, ubiquitin-specific proteases (USPs) 20 and 33, thus, inhibiting lysosomal trafficking when concomitantly promoting receptor recycling from the late-endosomal compartments as well as resensitization of recycled receptors at the cell surface. Dissociation of constitutively bound endogenously expressed USPs 20 and 33 from the b 2 AR immediately after agonist stimulation and reassociation on prolonged agonist treatment allows receptors to first become ubiquitinated and then deubiquitinated, thus, providing a 'trip switch' between degradative and recycling pathways at the late-endosomal compartments. Thus, USPs 20 and 33 serve as novel regulators that dictate both post-endocytic sorting as well as the intensity and extent of b 2 AR signalling from the cell surface.
Introduction
The receptor intracellular trafficking is an essential process that allows plasma-membrane localized seven-transmembrane receptors (7TMRs, also known as G-protein-coupled receptors, GPCRs) to generate adaptive responses to external stimuli (Tan et al, 2004; Drake et al, 2006; Moore et al, 2007) . Adaptor proteins called b-arrestins 1 and 2, which bind the receptor on receptor phosphorylation by the G-proteincoupled receptor kinases (GRKs), mediate agonist-stimulated 7TMR endocytosis (Ferguson, 2001; DeWire et al, 2007) . Owing to its involvement in severe pathologies, including heart failure and asthma, b 2 adrenergic receptor (b 2 AR) trafficking has been extensively studied. The b 2 AR and b-arrestin interaction leads to receptor desensitization as well as internalization into clathrin-coated pits. After internalization into early endosomes, the b 2 ARs are rapidly recycled back to the plasma membrane promoting functional resensitization of receptor signalling (Pippig et al, 1995) . However, during prolonged exposure to agonists, b 2 ARs also sort from endosomes to lysosomes and are degraded (Moore et al, 2007; Shenoy et al, 2008) . This downregulation process represents a critical means of regulating the number of receptors at the cell surface (Drake et al, 2006) , thereby influencing the intensity of physiological responses to b-agonists, many of which are used as therapeutic agents.
For the b 2 AR and several other 7TMRs, receptor ubiquitination serves as a necessary modification for receptor degradation in the lysosomal compartments (Shenoy, 2007) . On the other hand, ubiquitination of b-arrestin2 regulates the initial step of receptor endocytosis and signalling of 7TMRs (Shenoy et al, 2001; DeWire et al, 2007) . Additionally, b-arrestin2 recruits the HECT-domain containing E3 ligase Nedd4 and mediates ubiquitination and subsequent lysosomal degradation of the b 2 ARs (Shenoy et al, 2008) . Internalized ubiquitinated receptors are also recognized by a conserved set of endosome-associated proteins known as the ESCRT complexes, which are suggested to promote receptor translocation to the intralumenal vesicles of multivesicular bodies and facilitate lysosomal degradation (Saksena et al, 2007) .
Ubiquitination is a reversible process and deubiquitinating enzymes (DUBs) remove the ubiquitin moieties from ubiquitinated substrates. About 100 putative genes in the human genome encode DUBs, which are divided into five distinct subclasses of which the ubiquitin-specific protease (USP) subclass represents the bulk of the human DUBs (Nijman et al, 2005) . It is thought that ubiquitination and deubiquitination processes are choreographed by adaptors that bind both these enzymes. As b-arrestin2 serves as an adaptor to bring the E3 ubiquitin ligase Nedd4 to the b 2 AR, we wondered if it could have a dual role in escorting a DUB to modulate receptor ubiquitination. Recently, we discovered that b-arrestins bind the DUB , USP33 (Shenoy et al, 2009) , and herein we report our findings on how USP33 and its homologue USP20 modulate post-endocytic trafficking of the b 2 AR.
Results

USP33 inhibits the agonist-stimulated ubiquitination and lysosomal trafficking of the b 2 AR
To evaluate if USP33 affects receptor ubiquitination, we overexpressed HA-USP33 in HEK-293 cells stably transfected with Flag-b 2 ARs and analysed receptor ubiquitination in response to isoproterenol (Iso) stimulation by immunoprecipitation and western blotting ( Figure 1A and B). Iso stimulation resulted in receptor ubiquitination in cells with endogenous USP33 expression; however, this response was lost on overexpression of HA-USP33 in both HEK-293 ( Figure  1A and B) and COS-7 cells (Supplementary Figure S1 ). This diminution of ubiquitin signals in USP33-containing samples is not due to a defect in receptor activation because agoniststimulated receptor phosphorylation at the earlier documented GRK sites was normal ( Figure 1A ; Supplementary Figure  S1 , pb 2 AR blot). The low level of receptor ubiquitination detected under basal conditions was eliminated on USP33 overexpression suggestive of a constitutive b 2 AR-USP33 interaction. HA-USP33 specifically interacted with the b 2 AR under basal as well as in agonist-stimulated conditions as assessed by immunoblotting ( Figure 1A ).
Agonist-stimulated receptor ubiquitination has been shown earlier to serve as a signal for lysosomal degradation (Shenoy et al, 2008) . As HA-USP33 overexpression inhibits receptor ubiquitination, we anticipated that it would cause a lag in lysosomal trafficking of the b 2 AR. To assess this, we stimulated HEK-293 cells stably expressing Flag-b 2 AR-mYFP with or without co-expressed HA-USP33 with Iso and determined receptor colocalization with the late-endosomal/ lysosomal marker protein LAMP2. In cells with endogenous USP33 expression, we observed B60% colocalization of the b 2 AR and LAMP2 ( Figure 1C and E). In contrast, in cells overexpressing HA-USP33, we detected only B20% colocalization of LAMP2 and the b 2 AR ( Figure 1D and E). In HEK-293 cells, on immunostaining with anti-USP33 ( Figure 1D ; Supplementary Figure S2 ) or anti-HA (Supplementary Figure S2A) antibodies, overexpressed USP33 is visualized in the perinuclear regions and in small vesicles distributed throughout the cytoplasm and near the plasma membrane. Unfortunately, we were unable to detect endogenous USP33 by immunostaining with anti-USP33 antibodies. In quiescent cells, we detected colocalization of HA-USP33 and the b 2 AR at the plasma membrane (Supplementary Figure S2B) , and in agonist-stimulated cells, we observed the b 2 AR-positive vesicles being partially or wholly enveloped by USP33-positive vesicles ( Figure 1D ; Supplementary Figure S2B ). We did not observe any differences in receptor distribution between cells with endogenous or overexpressed USP33 under unstimulated conditions or on Iso stimulation for o6 h (Supplementary Figure S2B and data not shown). However, after 6 h of Iso stimulation, in cells overexpressing HA-USP33, the b 2 ARs re-localized at the plasma membrane or were found in small vesicles close to the plasma membrane, suggesting that receptors have recycled (compare the b 2 AR panels in Figure 1C and D). Overall, USP33 overexpression leads to an inhibition of receptor ubiquitination accompanied by a significant decrease in lysosomal trafficking as well as an increase in the plasma-membrane reappearance of the b 2 AR after 6 h Iso stimulation.
Catalytically inactive USP33 mutants do not inhibit the agonist-stimulated ubiquitination and lysosomal trafficking of the b 2 AR USP33 is a cysteine protease and its enzymatic activity relies on the thiol group of a cysteine in the active site. Deprotonation of this cysteine (C214 in HA-USP33) is assisted by a histidine (H683 in HA-USP33), which is polarized by an aspartate residue. These three residues make up the catalytic triad ( Figure 2A ). We generated inactive USP33 mutants by altering the cysteine 214 to a serine (USP33-CYS) and/or the histidine 683 to glutamine (USP33-HIS) and tested the deubiquitinating activity of HA-tagged (wild type) WT and mutant enzymes purified from COS-7 cells in an in vitro assay using polyubiquitin chains as substrates ( Figure 2B and C). Monoubiquitin accumulated due to the disassembly of either lysine 48 -or lysine 63 -linked polyubiquitin chains in the presence of USP33-WT and a generic DUB (isopeptidase T), but not USP33 mutants ( Figure 2C and data not shown).
We tested the effects of USP33-HIS, USP33-CYS and the double mutant USP33-CYS.HIS, which had comparable receptor interactions (Supplementary Figure S3 ; Figure 2D ) on both ubiquitination and trafficking of the b 2 AR ( Figure 2D -G and data not shown). In cells coexpressing Flag-b 2 AR and either USP33-HIS, USP33-CYS or USP33-CYS.HIS, receptor was ubiquitinated to identical levels as in cells transfected with vector and Flag-b 2 AR ( Figure 2D and E and data not shown). In contrast, as in Figure 1 , no agonist-induced ubiquitination was seen on WT USP33 overexpression along with Flag-b 2 AR ( Figure 2D and E). After 6 h of Iso stimulation, unlike USP33-WT that led to a decrease in lysosomal trafficking ( Figure 2F , right panel second row), USP33-HIS, USP33-CYS.HIS or USP33-CYS did not affect b 2 AR-LAMP2 colocalization ( Figure 2F and G and data not shown). At 6 h of Iso stimulation, receptor degradation as measured by [
125 I]-(À)iodocyanopindolol ( 125 I-CYP) binding was o10% in cells with endogenous USP33 expression, whereas there was no degradation in cells overexpressing HA-USP33 (not shown). Receptor degradation after 24 h Iso treatment was also dramatically reduced by the coexpression of USP33 (24 ± 2%: pCDNA3 versus 11 ± 1.2%: USP33-WT, Figure 2H ), but not catalytically inactive USP33 (21±0.5%: USP33-CYS.HIS, Figure 2H ). These results show that the enzymatic activity of USP33 regulates b 2 AR ubiquitination and modulates receptor degradation in the late-endosomal/ lysosomal compartments.
Role of deubiquitination in b 2 AR recycling
As USP33 activity appears to not only inhibit lysosomal trafficking and degradation, but actually promote the plasma-membrane localization of receptors ( Figures 1D and 2F ), we sought to quantify the resulting change in the absolute amount of cell-surface receptors using radioligand binding. We stimulated HEK-293 cells with stable b 2 AR expression for 6 h with Iso, performed agonist washout to enhance recycling and measured cell-surface receptors by 3 H-CGP12177 binding before and after agonist washout. In cells transfected with pcDNA3, a 30-40% increase in surface receptors was detected at the end of the 2-h wash period ( Figure 3A ). This increase was not affected by the addition of 5 mg/ml cycloheximide (protein synthesis inhibitor) before Iso stimulation and, therefore, is not due to newly synthesized receptors (data not shown). Overexpression of USP33 resulted in a 65-70% increase in cell-surface receptors-as that of USP33-HIS, which led to B35-45% increase ( Figure 3A) . If the catalytically inactive mutant functioned as a 'dominant negative', we would have observed some inhibition of receptor recycling. We theorized that the lack of a 'dominant-negative' effect could be attributed to the presence of a related enzymatic activity that functions in receptor deubiquitination and trafficking. In fact, mammalian cells express a homologue of USP33, namely USP20 (Supplementary Figure S4) , and its overexpression produced equivalent increasing effects on receptor recycling as that by USP33 ( Figure 3B ). Overexpression of USP20-HIS (H643Q) mutant had similar effects on recycling as that induced by USP33-HIS mutant ( Figure 3B ). Moreover, USP20 overexpression inhibited receptor ubiquitination, whereas catalytically inactive mutants, USP20-HIS, USP20-CYS (C154S) and USP20-CYS.HIS (C154S.H643Q), did not ( Figure 4A and B and data not shown). USP20 inhibited lysosomal trafficking of the b 2 AR, whereas USP20-CYS.HIS mutant led to B74% colocalization of b 2 AR-LAMP2 after 6 h of Iso stimulation ( Figure 4C and D). As a reciprocal effect, we found more membrane receptors in USP20-containing cells than USP20-CYS.HIS after 6 h of Iso stimulation. Similar to USP33, USP20 was also detected in vesicles by immunostaining. These vesicles mostly enveloped the b 2 AR-containing vesicles; some colocalization with LAMP2 was also seen, which was more pronounced for the USP20-CYS.HIS mutant than the WT ( Figure 4C ). These results suggest that both USPs 33 and 20 function to recognize and deubiquitinate the internalized b 2 AR cargo and play key roles in promoting receptor recycling.
To address the combined and individual roles of the two DUBs, we resorted to siRNA-mediated knockdown of endogenously expressed USPs 20 and/or 33. We tested the effects of either single or double knockdowns of USPs 20 and 33 by two separate siRNA oligonucleotides (20-1, 20-2, 33-1 and 33-2 targeting different regions) on receptor recycling ( Figure 5A ). When either USPs 33 or 20 was depleted, we did not observe a significant decrease in receptor recycling. In contrast, when we depleted both USPs 33 and 20 by siRNA transfections, we observed a complete inhibition of receptor recycling ( Figure 5A ). We could achieve 495% decrease in each protein by the simultaneous knockdown of USPs 20 and 33 ( Figure 5B ), whereas individual knockdowns had an effect of increasing (20-1, 20-2 and 33-2) or decreasing (33-1) protein levels of the second DUB. As a result, we detected either a slight increase or decrease in receptor recycling in the single knockdown cells compared with control cells. These data suggest that USPs 20 and 33 have redundant functions and one of the enzymes is able to compensate for the absence of the other and mediate b 2 AR trafficking. Receptor recycling is impaired only when both activities are eliminated.
If receptor deubiquitination subserves sorting of receptors to a recycling route, then the absence of ubiquitin modification on the b 2 AR should have a similar effect. To evaluate this, we compared recycling of WT-b 2 AR with that of a lysineless b 2 AR (0K-b 2 AR) that is not ubiquitinated (Shenoy et al, 2001) . The 0K-b 2 AR recycled to a significantly higher extent than the WT-b 2 AR, confirming that absence of ubiquitin moieties on the receptor efficiently directs them to recycle back to the plasma membrane ( Figure 5C ). Moreover, the simultaneous knockdown of USPs 20 and 33 that inhibits WT recycling ( Figure 5A ) did not affect 0K-b 2 AR recycling ( Figure 5D ), suggesting that USP activity targets only ubiquitinated receptors during post-endocytic sorting.
USPs 33 and 20 are required for b 2 AR resensitization on recycling from late-endosomal/lysosomal compartments On recycling to the plasma membrane, b 2 ARs are known to functionally recover or 'resensitize' such that their responsiveness to agonist is restored. To ascertain the effects of USPs 33 and/or 20 knockdowns on receptor resensitization, we used the cAMP biosensor (ICUE2) (Violin et al, 2008) and tested the cAMP responses by FRET microscopy. In cells with stable transfections of ICUE2 and the b 2 AR, the Isostimulated cAMP responses were identical irrespective of control or USPs 20 and 33 siRNA transfections ( Figure 6A , top row panels). In cells that have been pre-exposed to agonist for 6 h, we did not observe any cAMP response in control as well as USP-depleted cells ( Figure 6A , middle panels). However, in cells that have been treated with agonist for 6 h followed by a 2-h washout, we observed cAMP accumulation only in the control cells, but not in the USPdepleted cells ( Figure 6A , lowest panels and 6B). Single knockdown of either USP leads to a similar response as in control cells (not shown). As receptor recycling is close to zero in cells lacking both USPs 20 and 33 ( Figure 5A ), this defect in resensitization could be attributed to a lack of repopulation of receptors at the cell surface. If the USP enzymes regulate just recycling, then we should observe an increase only in recycling, but not in receptor resensitization, if we overexpress these enzymes. On the other hand, if USPs 33 and 20 regulate receptor recycling as well as resensitization, then overexpression of USPs 33 or 20 would result in an augmentation of both recycling and resensitization events. Indeed, when we overexpressed USPs 33 or 20 in the ICUE2 stable cells, we observed a significant increase in cAMP production measured after agonist wash ( Figure 6C and D) . Additionally, this effect was lost on coexpression of the catalytically inactive mutants ( Figure 6C and D) , suggesting that USPs 20 or 33 enzymatic activity is required for b 2 AR resensitization. These data suggest that receptor deubiquitination, recycling and resensitization are intimately linked events and that USPs 20 and 33 are important regulators that connect and balance these pathways.
Knockdown of USPs 20 and 33 results in increased agonist-stimulated ubiquitination, lysosomal trafficking and degradation of the b 2 ARs As shown in Figure 7A and B, simultaneous depletion of USPs 20 and 33 resulted in a dramatic increase in receptor ubiquitination in response to Iso stimulation. Furthermore, on analysing the cell lysates, we found a dramatic reduction in the monomeric form of the receptor at 6 h of Iso stimulation along with the appearance of numerous low-molecular weight bands as detected by a b 2 AR-specific antibody ( Figure  7A , lowest blot panel). When we treated cells with a lysosomal inhibitor (leupeptin) along with Iso, the monomeric b 2 AR was stabilized and the low-molecular weight bands were minimized ( Figure 7C ). Correlating with the increase in receptor ubiquitination, we also detected a more robust colocalization of b 2 AR and LAMP2 on depleting USPs 20 and 33 than in control cells (Figure 7D and E; Supplementary Figure S5 ). This effect was most pronounced at 6 h stimulation, although we did observe a small increase in receptor-LAMP2 colocalization in quiescent cells and on 1 h Iso treatment ( Figure 7D; Supplementary Figure S5 ). In cells that are depleted of both USPs 20 and 33, immunostaining of the b 2 AR is much weaker than in control cells at 6 h Iso stimulation, suggesting that internalized receptors are taken through a rapid path of destruction. Additionally, as determined by 125 I-CYP binding, receptor degradation increased by about 10-12 folds at 6 h of Iso stimulation in the absence of USPs 20 and 33 expression ( Figure 7F) . The above effects on Figure 8A and data not shown). Earlier identified proteins such as NHERF1/ EBP50, N-ethylmaleimide (NEM) sensitive fusion protein and GASPs, which regulate receptor trafficking, interact at the carboxyl-tail (CT) region of the b 2 AR (Marchese et al, 2008) . However, we could not detect USP33 binding to GSTb 2 AR C tail (residues 329-413) fusion protein. In these GSTpull down assays, we detected a weak interaction of USP20 with the receptor tail ( Figure 8B and C) . On the other hand, both USPs 20 and 33 bound to the receptor third loop (residues 218-276) GST-fusion protein ( Figure 8B and C) . The above in vitro data suggest that receptor USP interaction is direct and USPs 20 and 33 are likely recruited to membraneresident receptors in quiescent cells. Indeed, isolated b 2 AR immunoprecipitates contained detectable amounts of endogenous USP33 as well as USP20 in the absence of any agonist stimulation, suggesting that these enzymes are complexed with the cell-surface receptors ( Figure 8D and E, NS lanes). Interestingly, agonist stimulation for 5-15 min resulted in a significant decrease in the amounts of endogenous USP enzymes co-precipitating with the b 2 AR ( Figure 8D and E), suggesting that these enzymes have dissociated from the activated receptor complexes. However, the total levels of USPs 20 and 33 did not decrease on agonist stimulation as assessed by western blotting whole cell extracts ( Figure 8D ), and hence, this decrease in the detection of USPs 20 and 33 was not from protein degradation. The exact reason for the dissociation of endogenous USPs 20 and 33 is not known. At endogenous levels, increased affinity of other proteins that dynamically interact with activated receptors could compete off bound endogenous USPs, whereas on USP overexpression such displacements may be ineffective (Figures 1 and 2;  Supplementary Figure S3) . However, beyond 3 h of Iso treatment, we observed a reassociation of b 2 AR-USP enzymes, AR expression were transiently transfected with either control (CTL), or two separate siRNA targeting each type of USP singly or combined. *Po0.05, **Po0.01, one-way ANOVA between 6 h Iso and 6 h Iso þ wash in each group as indicated. Each 6 h sample is significantly different (***Po0.001) from the NS sample (not indicated). Additionally, the double siRNA transfections are significantly different (***Po0.001) from the CTL at 6 h Iso þ wash, by two-way ANOVA, (n ¼ 5-10). (B) The 30 mg of lysate samples from each siRNA transfection were analysed for USP20 (top) and USP33 (bottom) levels by immunoblotting. (C) Receptor recycling was determined in HEK-293 cells transiently transfected with the b 2 AR WT or the 0K-b 2 AR and cell-surface receptor expression analysed as in (A). Each receptor type showed significant amount of recycling as indicated (*Po0.05 and ***Po0.001) and internalization at 6 h Iso (not indicated, ***Po0.001). The 0K-b 2 AR recycling was significantly higher than WT recycling (**Po0.01), two-way ANOVA, n ¼ 3. (D) The 0K-b 2 AR recycling was analysed as above in cells with CTL or USPs 20 þ 33 double knockdown. **Po0.01, between 6 h Iso and 6 h Iso þ wash in each case, one-way ANOVA, Bonferroni comparison. CTL and USP siRNA groups did not differ, two-way ANOVA (n ¼ 4).
with the interaction levels reaching close to basal conditions. Thus, although endogenous USPs dissociate from the receptors immediately after agonist activation, they evidently recognize and reassociate with internalized receptors. After 6 h of Iso stimulation, internalized b 2 ARs are mostly localized in LAMP2-positive compartments; therefore, USPs 20 and 33 recognize the ubiquitinated receptor cargo that traffic to late-endosomal/lysosomal compartments, deubiquitinate the receptors and promote their recycling.
The tag team of b 2 AR, USP33 and b-arrestin2
As we observed b 2 AR-USP33 binding in the absence of agonist stimulation and as it is well established that b-arrestins are transiently recruited to the b 2 ARs at the plasma membrane only on agonist activation, we believe that b 2 AR-USP33 interaction can prevail before b-arrestin recruitment. However, as b-arrestins bind USP33 as well (Shenoy et al, 2009) , we sought to analyse how these various interactions correlate with agonist treatment. As seen above, at early time points of Iso stimulation, endogenous USP33 dissociates from the activated b 2 ARs. In marked contrast, when we isolated b-arrestin2 immunoprecipitates (representing the total cellular pool of b-arrestin), we observed an increase in b-arrestin-USP33 interaction at early time points of Iso stimulation and the interaction diminished beyond 1 h of agonist treatment ( Figure 9A and B) . Thus, although we observe a decrease in receptor-USP33 interaction at short times of agonist activation, we detect a reciprocal pattern of increase in b-arrestin2-USP33 interaction. Collectively, our findings suggest that when b-arrestin2 facilitates b 2 AR ubiquitination by recruiting Nedd4 (Shenoy et al, 2008) , its adaptor function might actually serve to remove the DUB from the activated b 2 AR to facilitate receptor ubiquitination.
Discussion
We show that two closely related DUBs, USP33 (also known as VDU1) (Li et al, 2002a) and USP20 (also known as VDU2) (Li et al, 2002b) , can bind the b 2 AR and orchestrate receptor recycling and resensitization. Agonist stimulation of the b 2 AR leads to ubiquitination and lysosomal degradation of the receptor, but overexpression of USPs 33 and 20 counteracts these effects and promotes receptor recycling and resensitization. Additionally, knockdown of both USPs 33 and 20 abolishes receptor recycling and resensitization, but enhances ubiquitination as well as lysosomal degradation. b-arrestin2 serves as an essential endocytic adaptor for the b 2 AR, recruits endocytic and signalling proteins and escorts the E3 ubiquitin ligase Nedd4 to the activated receptor complex (DeWire et al, 2007; Shenoy et al, 2008) . As USP33 was identified as a b-arrestin interacting partner (Shenoy et al, 2009) , we expected that b-arrestin2 would also bridge the interaction between the b 2 AR and USP33. Our data prove otherwise that USP33 is bound to the receptor before agonist-stimulation and b-arrestin translocation. Agonist-activated b 2 AR forms a weak and transient complex with recruited b-arrestins and the dissociation of b-arrestin2 has been correlated with its deubiquitination (Oakley et al, 2000; Shenoy and Lefkowitz, 2003) . In a related work (Shenoy et al, 2009 ), we show that conformational changes induced in b-arrestin2 in response to b 2 AR activation facilitates b-arrestin2-USP33 binding. USP33 deubiquitinates barrestin2 and disassembles b 2 AR-b-arrestin2 signalling complexes. Although the b-arrestins that are dissociating from the receptor can recruit USP33 present in the cytoplasmic compartments, the timing of these events suggests that USP33 constitutively bound to the cell-surface b 2 ARs could be transferred to the translocated b-arrestins leading to their deubiquitination and disengagement from the b 2 AR complex. We believe that there is a dynamic exchange of protein partners between the b 2 AR and b-arrestin when both proteins are in specific-'activated' conformations. Thus, the E3 ligase Nedd4 is released from b-arrestin2 to act on the receptor and USP33 is transferred from the receptor to bind b-arrestin2, thus, facilitating synchronized receptor ubiquitination and b-arrestin deubiquitination events. Ubiquitinated b 2 ARs begin to localize in late-endosomes/ lysosomes after 3 h of Iso stimulation, and considerable colocalization of LAMP2 and b 2 ARs is observed only after 6 h of Iso stimulation (Hanyaloglu and von Zastrow, 2007; Shenoy et al, 2008) . As the timing of localization of internalized receptors in LAMP2-positive compartments matches with that of b 2 AR-USP reassociation, we believe that these DUBs recognize and bind the ubiquitinated b 2 AR cargo at the late endosomes. This leads to deubiquitination of the receptors preventing lysosomal degradation and facilitating receptor recycling. Overexpressed USPs persistently associate with the b 2 ARs and cause more striking effects of preventing lysosomal trafficking and recycling of the b 2 ARs by totally inhibiting receptor ubiquitination. The differences in the binding patterns of endogenous versus overexpressed USPs could simply be due to the abundance of protein in the latter condition. As the intracellular itinerary of activated b 2 ARs can involve an ensemble of dynamic interactions, the dissociation of endogenous USPs 20 and 33 could be due to a competition from other endogenously expressed b 2 AR interactors, which cannot effectively compete with the USP-receptor interaction observed under overexpression conditions.
As such, b 2 ARs are known to be stable proteins with a protein half-life of X24 h in the presence of Iso (Gagnon et al, 1998; Shenoy et al, 2001; Pan et al, 2003; Liang and Fishman, 2004) . The slow rate of b 2 AR degradation could be attributed to the deubiquitinating activities of USPs 20 and 33. With the elimination of these two DUBs, both agonist-stimulated ubi- quitination and receptor degradation are dramatically increased, whereas receptor recycling and resensitization are totally inhibited. We did not find any significant differences in receptor expression levels or internalization with either depletion or repletion of both USP enzymes, suggesting that their activity affects a specific step during post-endocytic sorting. However, receptor expression levels in cells transfected with WT USPs 20 or 33 were significantly elevated when compared with cells transfected with the corresponding inactive mutants. On the other hand, overexpression of USP4 that promotes cell-surface targeting of newly synthesized adenosine A2 receptors (Milojevic et al, 2006) did not affect b 2 AR ubiquitination or b 2 AR-LAMP2 colocalization (data not shown), thus, indicating that b 2 AR regulation involves specific USP isoforms. Interestingly, ubiquitination and lysosomal degradation of the growth factor receptor, EGFR, is regulated by two DUBs, USP8 (also known as UBPY) and AMSH (McCullough et al, 2004; Mizuno et al, 2005 Mizuno et al, , 2006 Bowers et al, 2006; Clague and Urbe, 2006) . AMSH is associated with endosomes and inhibits EGFR lysosomal trafficking. UBPY plays an opposite role as its deubiquitinating activity promotes EGFR downregulation. These studies indicate that DUB activity is an important check point for the lysosomal entry of internalized growth factor receptors and bear analogy with our findings on the roles of USPs 20 and 33 in b 2 AR trafficking. On the other hand, our studies show a novel connection between GPCR deubiquitination, recycling and receptor resensitization.
On acute agonist treatment, activated b 2 ARs internalize into early endosomes, subsequently become dephosphorylated and recycle to the plasma membrane. We did not find an inhibition of receptor recycling in USPs 20-and 33-depleted cells after acute agonist stimulation. As such, nonubiquitinated 0K-b 2 ARs, which internalize to the same extent as the ubiquitinated WT-b 2 ARs, recycle more efficiently at early (data not shown) as well as late time points than the WT-b 2 AR. The 0K-b 2 ARs do not colocalize with LAMP2 (data not shown), suggesting that they do not traffic to these compartments. Hence, we believe that the fast recycling route from early endosomal compartments mainly involves dephosphorylation of nonubiquitinated receptors, whereas the slow recycling of ubiquitinated receptors from deeper subcellular compartments is regulated perhaps by both DUB and phosphatase activities (Pitcher et al, 1995) . Future studies should reveal if the DUB-dependent recycling pathway could parallel or intersect other pathways showed for b 2 AR recycling (Odley et al, 2004; Hanyaloglu and von Zastrow, 2007; Millman et al, 2008) . It would be of interest also to determine if USPs 33 and 20 could functionally link some of the scaffolds involved in b 2 AR recycling and resensitization, although these earlier studies mostly characterized recycling events induced by acute agonist treatments (Hall and Lefkowitz, 2002; Hanyaloglu and von Zastrow, 2007) . Future challenges will also involve unravelling the mechanisms by which ubiquitination of the b 2 AR is preserved until the receptors sort to lysosomes as well as the identification of cofactors that facilitate or prevent the reassociation of receptors and DUBs at the late-endosomal compartments. The mechanisms that suppress DUB activity at further time points of Iso stimulation (24 h or more) to promote receptor degradation remain to be discovered.
As seen in our siRNA experiments, single knockdown of either USPs 20 or 33 does not affect receptor trafficking, suggesting that expression of one of these enzymes alone suffices to regulate the b 2 AR recycling. USPs 20 and 33 show 59% identity in their amino-acid sequence, which might explain their close functional relationship. Earlier studies have indicated their roles in proteasomal degradation of the transcription factor HIF-1 and the ER-associated type 2 iodothyronine deiodinase (Curcio-Morelli et al, 2003; Li et al, 2005) . Interestingly, ubiquitin chains that are lysine 48 linked are generally degraded by the 26S proteasomes, whereas the lysine 63 linkage is involved in tagging proteins for vesicular trafficking (Varadan et al, 2004) . In fact, in our in vitro deubiquitination assays, USP33 is capable of depolymerizing lysine 48 as well as lysine 63 polyubiquitin chains, indicative of its roles in lysosomal and proteasomal pathways.
This study establishes the importance of the dynamic process of ubiquitination/deubiquitination in the regulation of receptor trafficking and signalling. That GPCR recycling and resensitization could be coupled to deubiquitination occurring at late-endosomal/lysosomal compartments is a new concept. We show that USPs 20 and 33 are critical for receptor resensitization after prolonged agonist stimulation, thus, underscoring their role in rejuvenating the physiological hormonal responsiveness. Considering the pathophysiological importance of the b 2 AR (Rockman et al, 2002; Galandrin et al, 2007) , it certainly is a process that needs to be weighed in the design of new treatments, especially for diseases that involve chronic agonist stimulation or require long-acting agonist treatment such as in asthma. A process that would rescue the recycling of the receptor and consequently its resensitization would be very helpful to overcome side effects of such diseases and treatments.
Materials and methods
Reagents and plasmids
Anti-Flag M2 affinity gel, (À)-Iso, NEM, Fibronectin (Bovine plasma) were from Sigma. Collagen (rat tail) was from Roche. Polyubiquitin chains (K48-linked; K63-linked) and Isopeptidase T were from Boston Biochem. Antibodies and their suppliers were: anti-Flag M2 (Sigma), anti-ubiquitin P4D1 (Santa Cruz), antiubiquitin FK2H (Biomol), anti-b 2 AR H20 (Santa Cruz), anti-USP33 and anti-USP20 (Bethyl laboratories) and anti-LAMP2 H4B4 (Santa Cruz). Alexa 594, 488 and 633, conjugated secondary antibodies were from Invitrogen. Horseradish peroxidase-conjugated secondary antibodies and (À)-[ 3 H]CGP-12177 were from GE/Amersham. The cAMP biosensor ICUE2 (indicator of cAMP using Epac) was kindly provided by Dr Jin Zhang. The human USP20/pCMV4 plasmid (NM_006676.4) is a purchase from OriGene Technologies. Mutations converting cysteine to serine residue and histidine to glutamine residue were individually introduced into USPs 33 or 20 proteins by site-directed mutagenesis. All resulting plasmids were verified by DNA sequencing.
Immunofluorescence staining and confocal imaging HEK-293 cells stably expressing Flag-b 2 AR-mYFP were transiently transfected with HA-USP33 WT or mutants. The 24 h posttransfection cells were plated on collagen-coated 35-mm glass bottom plates and 24 h later, cells were starved for 1 h in serum-free medium, then stimulated, fixed with 5% formaldehyde diluted in PBS containing calcium and magnesium, permeabilized with 0.08% Triton X-100 (cat# T-9284, Sigma) in PBS containing 2% bovine serum albumin for 30 min and incubated with appropriate primary antibody O/N at 41C, followed by the respective secondary antibody. Longer permeabilization times prevented detecting USPs associated with vesicles. Confocal images were obtained on a Zeiss LSM510 laser-scanning microscope using multitrack sequential excitation (488, 568 and 633 nm) and emission (515-540 nm, GFP; 585-615 nm, Texas Red; 650 nm, Alexa 633) filter sets. The scale bars included in all confocal panels represent 10 mm. For the quantification of b 2 AR/LAMP2 colocalization, b 2 AR was pseudocoloured green, LAMP2 was pseudo-coloured red, the USP channel was turned off in USP-positive cells and the merged images of 10-15 randomly chosen cells for a specified condition were analysed for the percentage of yellow (colocalization of LAMP2 and b 2 AR) vesicles against the total b 2 AR (green þ yellow) vesicles.
